Skip to main content
رجوع
Watch Compare

Cadrenal Therapeutics, Inc.

جودة البيانات: 83%
CVKD
NASDAQ Manufacturing Chemicals
KWD 4.85
▲ KWD 0.04 (0.83%)
6 months return
—
Momentum
Neutral
ROE
-376.39%

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-376.39%
أقل من متوسط القطاع (-54.47%)
ROIC-302.38%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio3.02
Interest CoverageN/A

التقييم

PE (TTM|NTM)
-0.92 | -1.23
أعلى من متوسط القطاع (-1.50)
P/B Ratio4.46
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -12.61 M

Price History

الاتجاهات المالية

السعر المستهدف للمحللين

3 محللين
Buy
+470.4%
upside to target
الحالي
KWD 4.85
Consensus Target
KWD 27.67
KWD 13.00
أدنى
KWD 45.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-1.23
ربحية السهم المستقبلية
-KWD 3.91
الإيرادات المقدّرة
0.0

مفاجآت الأرباح

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -KWD 1.58 · Rev Est: 0.0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -KWD 2.09 -KWD 1.87 -KWD 1.31 -KWD 1.41 — —
Estimate -KWD 2.15 -KWD 1.78 -KWD 1.55 -KWD 1.21 -KWD 1.58 -KWD 1.64
المفاجأة +2.79% -5.35% +15.48% -16.53% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -376.39% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -13.24 M
ROE -376.39% ROA -263.01%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -12.61 M
ROIC -302.38% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 3.02
Debt / Equity N/A Current Ratio 3.02
Interest Coverage N/A Asset Turnover N/A
Working Capital 2.73 M Tangible Book Value 2.73 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0.92 · EV/EBITDA: N/A
P/E Ratio -0.92 Forward P/E -1.23
P/B Ratio 4.46 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -103.44%
Market Cap 12.19 M Enterprise Value 8.33 M

Per Share

EPS: -6.64 · FCF/Share: -5.03
EPS (Diluted TTM) -6.64 Revenue / Share N/A
FCF / Share -5.03 OCF / Share -5.03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 95.24% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 95.24%
SBC-Adj. FCF -14.52 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2022 FY2023
Revenue — — — —
Net Income -13.24 M -10.65 M -6.71 M -8.36 M
EPS (Diluted) -6.64 -8.73 -0.85 -0.62
Gross Profit — — — —
Operating Income -13.46 M -10.96 M -2.70 M -7.63 M
EBITDA — — — —
R&D Expenses 4.10 M 4.21 M 136,802.0 4.08 M
SG&A Expenses — — — —
D&A — — — —
Interest Expense — 3,534.0 40,192.0 —
Income Tax — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2022 FY2023
Total Assets 4.33 M 10.12 M 778,174.0 8.52 M
Total Liabilities 1.59 M 2.68 M 6.33 M 826,875.0
Shareholders' Equity 2.74 M 7.44 M -5.55 M 7.69 M
Total Debt — — — —
Cash & Equivalents 4.01 M 10.00 M — 8.40 M
Current Assets 4.32 M 10.11 M 727,596.0 8.49 M
Current Liabilities 1.59 M 2.68 M 1.33 M 826,875.0

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1605 نظير)
المقياس السهم وسيط القطاع
P/E -0.9 -1.5
P/B 4.5 1.6
ROE % -376.4 -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.9
D/E — 0.3